← All trials
NCT01506414
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2009
- Primary completion
- Aug 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 91
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Shandong UniversityLead sponsor
- Shandong UniversityOverall official - principal investigator
- Shandong UniversitySponsor investigator
- Shandong Provincial HospitalCollaborator
- Zhejiang UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sichuan UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Tsinghua UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.